APUS (Apimeds Pharmaceuticals US) Short-Term Debt to Capital

Apimeds Pharmaceuticals (APUS) is protected by exclusive patents on bee toxins for combating brain inflammation, operating under strict FDA oversight. Development relies on automated biomaterial processing, which streamlines laboratory testing. This chart for the stock demonstrates a debt-to-equity ratio of 0.13. However, the lack of operating leverage during the expansion of protein research is leading to increased medical costs.

This indicator determines the company's dependence on obligations with a maturity of up to one year relative to its equity, measuring liquidity risk and the potential for asset dilution. By analyzing the short-term liabilities to equity chart, an investor can assess the extent to which the expansion of the Apimeds Pharmaceuticals (APUS) biotech system in the apitoxin-based neuropreparations segment is financed through risky short-term loans.